Smith Mark Douglas Buys Shares of Phreesia, Inc.

Smith Mark Douglas made a notable purchase of Phreesia, Inc. shares recently. On June 24, 2026, he acquired 19,290 shares of the health information services company at an average price of $9.59 per share. This transaction was valued at approximately $184,991 and was not part of a pre-planned trading program.

Insider Buying and Selling at Phreesia, Inc.

Several insiders at Phreesia, Inc. were active around the same time. On June 24, 2026, Lainie Goldstein, Ramin Sayar, Gillian Munson, and Lisa Egbuonu-Davis each purchased 19,290 shares at the same price of $9.59 per share. These transactions were not pre-planned. Additionally, on June 25, 2026, Lisa Egbuonu-Davis sold 2,546 shares at an average price of $9.53 per share as part of a planned transaction.

Other Institutional Activity in Phreesia, Inc.

Institutional investors have also been active in Phreesia, Inc. PALE FIRE CAPITAL SE opened a new position with 8,649,329 shares worth about $72.5 million. BlackRock, Inc. increased its holdings by 284,445 shares, bringing its total to 5,920,469 shares valued at approximately $49.6 million, marking a 5% increase. AQR Capital Management LLC boosted its stake by a significant 1,415,465 shares, now holding 1,852,559 shares worth about $15.5 million, a 323.8% increase.

Phreesia, Inc. Stock Down 17.1%

As of Saturday, shares of Phreesia, Inc. (NYSE:PHR) traded near $9.13. The company has a market capitalization of $622.4 million. Its P/E ratio stands at 62.9, with a forward P/E of 6.3, and a beta of 0.884. Over the past year, the stock has seen a low of $7.77 and a high of $32.76, with a 50-day moving average of $9.38 and a 200-day moving average of $15.21. Phreesia maintains a current ratio of 1.76 and a quick ratio of 1.43, with a debt-to-equity ratio of 25.78.

Recent Earnings

Phreesia, Inc. reported revenue of $495.6 million, reflecting a growth of 12.9%. The company's net margin was 1.85%, and it achieved a return on equity of 2.86%. Earnings per share were $0.16. The next earnings report is expected on September 3, 2026.

Analysts Set New Price Targets

On May 29, 2026, Truist Securities maintained its hold rating for Phreesia, Inc. with a price target of $12.00. Similarly, Citigroup and Canaccord Genuity maintained their hold and buy ratings, respectively, with price targets of $12.00 and $16.00. The consensus among 17 analysts is a 'buy' rating with a mean price target of $13.94.

About Phreesia, Inc.

Phreesia, Inc. operates in the healthcare sector, specifically in health information services. The company provides a software and payment platform that helps healthcare organizations manage appointments, patient communications, and payments more efficiently. Based in Wilmington, Delaware, Phreesia serves a variety of healthcare providers, including hospitals and ambulatory practices, with solutions that enhance patient engagement and streamline operations. Led by CEO Evan Roberts, the company employs approximately 1,789 people.

Bottom Line

Smith Mark Douglas's recent purchase of Phreesia shares highlights ongoing insider interest in the company. Phreesia is a key player in healthcare IT, providing essential services to medical providers. Investors often track insider purchases as a potential indicator of confidence in the company's future. However, it's important to remember that these transactions are disclosed after they occur and may not reflect current intentions.